Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business
Valo Health, Inc.
About
  2. Companies
  3. Valo Health, Inc.
  4. News
9 News & Press Releases found

Valo Health, Inc. news

Valo`s David Berry to Deliver Keynote at Founders Network`s fnSummit 2022

Valo Health, Inc (“Valo”), the tech­nol­o­gy com­pa­ny focused on trans­form­ing the drug dis­cov­ery and devel­op­ment process using human-cen­tric data and arti­fi­cial intel­li­gence, announced that David Berry, founder & 

Jan. 13, yyyy

Valo Health to Present at the 41st Annual J.P. Morgan Healthcare Conference

Valo Health, Inc. (“Valo”), the tech­nol­o­gy com­pa­ny using human-cen­tric data and arti­fi­cial intel­li­gence (AI) pow­ered com­pu­ta­tion to trans­form the drug dis­cov­ery and de

Jan. 3, yyyy

Valo Health - FDA Collaborative Study in Human Cardiac Tissues Demonstrates Potential to Predict Clinical Efficacy of Cardiac Contractility Modulation Devices to Treat Heart Failure

Valo Health, Inc (“Valo”) shared the ini­tial results of a col­lab­o­ra­tive study with the U.S. Food and Drug Admin­is­tra­tion (FDA), demon­strat­ing the poten­tial of Val­o’s Biowire plat­form to pre­dict clin­i­cal effi­

Dec. 14, yyyy

Valo Health To Participate in Piper Sandler`s 34th Annual Healthcare Conference

Valo Health, Inc ("Valo"), the technology company focused on transforming the drug discovery and development process using human-centric data and a

Nov. 16, yyyy

KSM research and innovation center and Valo Health announce first of its kind multiyear collaboration to spearhead preventive care and personalized medicine for patients

Kahn-Sagol-Mac­cabi (KSM), the research and inno­va­tion cen­ter of Israel’s lead­ing HMO — Mac­cabi Health­care Ser­vices, and Valo Health, Inc. (“Valo”), the tech­nol­o­gy com­pa­ny focused on trans­form­ing the drug dis­cov­ery and devel­op­ment process using human-cen­tric data and arti­fi­cial intel­li­gence, ann

Sep. 19, yyyy

Valo Health to Participate in UBS Biotechnology Virtual Private Company Symposium

Valo Health, Inc (“Valo”), the technology company focused on transforming the drug discovery and development process using human-centric data and artificial intelligence, announced that David Berry, founder & CEO of Valo will present at the UBS Biotechnology Virtual Private Company Symposium on September 22, 2022 from

Aug. 31, yyyy

Valo Announces First Patient Dosed in the OPL-0401 Phase 2 study of an oral ROCK1/2 inhibitor for the Treatment of Non-Proliferative Diabetic Retinopathy

Valo Health, Inc. (“Valo”), the tech­nol­o­gy com­pa­ny focused on trans­form­ing the drug dis­cov­ery and devel­op­ment process using huma

Aug. 18, yyyy

Valo Health Announces Publication of the Journal of Clinical Investigation of a New Therapeutic Approach to Improve CD8+ T Cell Function

Valo Health, Inc (“Valo”), the tech­nol­o­gy com­pa­ny focused on trans­form­ing the drug dis­cov­ery and devel­op­ment process using human-cen­tric data and arti­fi­cial intel­li­gence, announced a proof of con­cept for using its pre­clin­i­cal asset, OPL-0101, to tar­get CD8+ T cells, in the cur­

Jun. 2, yyyy

Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

Charles River Laboratories International, Inc. (NYSE: CRL) and Valo Health, Inc (“Valo”) have launched LogicaTM, an artificial intelligence (AI) powered drug solution that directly translates clients’ biological insights into optimized preclinical assets. Logica leverages Valo’s AI-powered Opal Computational Platform and Charles River’s leading preclinical expertise, providing clients with transformed drug discovery with a single integrated offering seamlessly tr

Apr. 27, yyyy